Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Focus of the Report: This report focuses on the use of intravenous (IV) ketamine for the treatment of chronic nonmalignant pain.
Technology Description: The hydrochloride (HCl) acid salt of ketamine is a rapid-acting phencyclidine anesthetic indicated for the induction of anesthesia prior to the administration of other general anesthetic agents, as a s…
Focus of the Report: Oral anticoagulation (OAC) is standard care to reduce the risk of stroke in patients with atrial fibrillation (AF) and risk factors for stroke. Limitations of OAC therapy have spurred the development of nonpharmaceutical approaches to prevent stroke in patients with AF by occluding the left atrial appendage (LAA). LAA occlu…
Retifanlimab is an investigational intravenous humanized monoclonal antibody that inhibits the activity of programmed death-1 (PD-1). By blocking PD-1, retifanlimab acts as an immune checkpoint inhibitor, freeing T cells to kill cancer cells and boosting immune system response against certain cancers. Retifanlimab is proposed as a monotherapy for locally advanced and metastat…
Evrysdi (risdiplam; formerly RG7916) is an oral small molecule splicing modifier of the survival motor neuron 2 (SMN2) gene indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.
Focus of the Report: This report focuses on venous sinus stenting (VSS) for treatment of idiopathic intracranial hypertension (IIH) that has failed to respond to available drug and conservative treatments.
Technology Description: VSS is an endovascular procedure performed via the jugul…
Amondys 45 (casimersen) is an intravenously administered antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
The WiSE CRT system is a wireless left ventricular pacing system that works with an implanted right ventricular pacemaker and/or defibrillator for patients in whom cardiac resynchronization therapy (CRT) is indicated.
Elivaldogene autotemcel (eli-cel) is a lentiviral-based gene therapy for treatment cerebral adrenoleukodystrophy (CALD).
TissueGene-C is an injectable solution of normal and genetically modified allogeneic human chondrocytes in development for the treatment of knee osteoarthritis.
Focus of the Report: This report evaluates the use of liquid sublingual immunotherapy (SLIT) for the treatment of allergic rhinitis in the United States.
Technology Description: Liquid SLIT involves the daily administration of a diluted dose of an allergen under the tongue, which allow…